Matrixx Investor Battle Could Spur Overdisclosure
The U.S. Supreme Court fight between Matrixx Initiatives Inc. and investors over whether the Zicam cold remedy maker should have revealed adverse event reports could change disclosure standards for consumer product...To view the full article, register now.
Already a subscriber? Click here to view full article